Pharmaceuticals

FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales

Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology

Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million

What's Going On With Arcutis Biotherapeutics Stock Monday?

Pharmaceuticals Recent News

Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline

Jazz Pharmaceuticals will add dordaviprone, a potential treatment for a rare brain tumor, to its growing oncology pipeline.

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

Walgreens Boots Alliance Stock Is Up More Than 6% On Monday: Here's What Happened

Walgreens Boots Alliance shares traded higher Monday following reports that multiple lenders are preparing to back a potential buyout from Sycamore Partners.

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.

Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.

Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is struggling with a bearish trend.

Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic colorectal cancer.

FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief

FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study

Tiziana Life Sciences recently discovered new immune biomarkers in SPMS patients treated with nasal foralumab.

Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses

FDA issues warning letter to Sanofi over its Genzyme facility, citing process deviations, equipment issues, and quality oversight lapses.

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.

Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Stock Of The Day: Will Johnson & Johnson Take The Market Lower?

Shares of Johnson & Johnson are flat in Monday's trading. But they continue to test support. If this support breaks, it could be bearish for the entire market.

Bipartisan Lawmakers Aim To Break Up Health Care Giants With New Legislation

Pharmacy-benefit managers (PBMs) have been scrutinized for their role in drug distribution for years. Now a bipartisan group of lawmakers is threatening to break up the companies behind these so-called drug middlemen.

Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts

Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are skeptical.

Stock Of The Day: Where Will The Eli Lilly Rally End?

Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it.

Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.